Allogene Therapeutics Inc (NYSE:ALLO) Q4 2019 Earnings Conference Call - Final Transcript
Feb 27, 2020 • 08:30 am ET
Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Allogene Therapeutics Fourth Quarter 2019 Conference Call. [Operator instructions] Please be aware that today's conference call is being recorded.
I would now like to turn the call over to Christine Cassiano, Chief Communications Officer. Ms. Cassiano, please go ahead.
Thank you, operator, and good morning. Before market opened today, Allogene issued a press release that provides a corporate update and financial results for the fourth quarter and full year ended December 31, 2019. This press release is available on our website at www.allogene.com. We remind listeners that today's call is being webcast on our website and will be available for replay.
Joining me on the call today are Dr. David Chang, President and Chief Executive Officer; Dr. Rafael Amado, Executive Vice President of Research and Development and Chief Medical Officer; and Dr. Eric Schmidt, Chief Financial Officer.
During today's call, we will be making certain forward-looking statements. These may include statements regarding the success and timing of our ongoing and planned clinical trials, regulatory filings, future research and development efforts, manufacturing capabilities and 2020 financial guidance, among other things. These forward-looking statements are based on current information, assumptions and expectations that are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements.
These and other risks are described in our periodic filings made with the Securities and Exchange Commission, including our Form 10-Q for the quarter ended September 30, 2019, as well as our upcoming Form 10-K for the year ended December 31, 2019. You are cautioned not to place undue reliance on these forward-looking statements and the company disclaims any obligation to update such statements.
I'll now turn the call over to Dr. David Chang.
Good morning, and thank you for taking time to join us on our call today to discuss our fourth quarter and the year ahead. I am extremely pleased with what we have accomplished in 2019. We completed the hiring of senior management, built world-class capabilities across critical functions and initiated the build-out of our GMP cell-manufacturing facility in Newark, California, making steady progress toward bringing the facility online in 2021. Most importantly, we initiated two clinical programs: ALLO-501 in relapsed and refractory non-Hodgkin lymphoma and ALLO-715 in relapsed and refractory multiple myeloma.
Our research team is also working toward advancing additional programs in next-generation cell-engineering technologies, which we plan to introduce into clinical trials in the coming years. It is still early in 2020, but we are continuing the momentum we created last year and working at an accelerated pace. This year we anticipate reporting initial data for two key clinical programs: ALLO-501 in the second quarter of this year and ALLO-715 in the fourth quarter. We also look forward to expanding our clinical portfolio as we progress our next IND candidate, ALLO-316, which targets CD70.
All 200-plus employees at Allogene remain singularly focused on